Fibrocor Therapeutics is discovering and developing a pipeline of novel drugs to treat patients with fibrotic diseases. Nearly 45% of all deaths in the developed world are attributed to some type of chronic fibroproliferative disease. There are currently only 2 approved treatments for idiopathic pulmonary fibrosis, both with limited efficacy.
Fibrocor is pioneering the use of tissue specific therapeutics in the field of precision medicine and in particular, Fibrosis. The company has partnered with leading research institutes in Toronto, Canada to aggregate and interrogate diseased fibrotic tissue samples in a number of organ systems to understand the genesis of the disease and its manifestations in fast progressing populations.